Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Azacitidine and Chidamide Maintenance in High-risk AML Post-Transplant
NCT05270200Phase 2Recruiting
- Sponsor
- Southern Medical University Zhujiang Hospital
- Start
- Feb 2022
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of azacitidine, tucidinostat in acute myeloid leukemia (AML), sponsored by Southern Medical University Zhujiang Hospital. Started Feb 2022; status: recruiting.
02
Drugs
azacitidinetucidinostat
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT05270200.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05270200.